MD, FIDSA, FECMM. Hematology &Oncology, Rheumatology, Intensive Care, Infectious Diseases. Tweets are my own & do not represent endorsements or medical advice
Joined July 2019
- Tweets192
- Following209
- Followers373
- Likes225
Pinned Tweet
1/2 📣 Grateful to co-organize the @ESCMID Online Education Course: Invasive fungal infections in critically ill patients: 22-23 Nov 2021 with @CornelyOliver endorsed by @efisg_escmid #ESGCIP #ESGICH Register here 👉bit.ly/3qAQHbV @UKKoeln looking forward to great talks
Philipp Koehler retweeted
👉Participate in @eurconfmedmycol ECMM Candida IV Study
🌍wide study on candidemia caused by non-albicans Candida
Requirement: clinical data & isolate (not req for C.auris)
Observation period: 04/2024 - 09/2025 Interested?
DM @Stella_A_I or @SarahSedik
Philipp Koehler retweeted
Die Forschungsarbeit des Studienzentrums Klinische Immunologie in der Klinik I für Innere Medizin an der #UniklinikKöln wird von der Dr. Heinz Lux-Stiftung mit insgesamt 180.000 Euro gefördert. Zur ganzen Meldung: uk-koeln.de/uniklinik-koeln/…
ALT Dr. Philipp Köhler, Oberarzt und Leiter des Schwerpunkts Klinische Immunologie und Rheumatologie, Foto: Michael Wodak
Philipp Koehler retweeted
👉Participate in ECMM Candida IV
🌎wide study on candidemia caused by non-albicans Candida spp.
Requirement: clinical data & isolate (not req for C.auris)
Reward: Reimbursement & Authorship
Observation period: 04/2024 - 09/2025
Interested? 📧 [email protected]
Philipp Koehler retweeted
Which #trial do we need? Shorter #antifungal treatment for #candidemia – challenging the 14-day dogma. @CMIJournal: sciencedirect.com/science/ar…
#fungalinfections #IFI
@nicobekaan @tim_friede @RosanneSprute @KoehlerPh @SalmantonGarcia @JannikStemler
Philipp Koehler retweeted
My interview for austrian national television on attributable mortality of candidemia and the ECMMCandida III study.
Great study @SalmantonGarcia @KoehlerPh @CornelyOliver and others!
@eurconfmedmycol @MedUniGraz on.orf.at/video/14235715/156…
Philipp Koehler retweeted
🔥📰
Attributable mortality of candidemia – Results from ECMM Candida III multinational European Cohort Study
Attributable mortality overall 18.1%, driven by non-albicans Candida.
🙏🏻 @SalmantonGarcia @KoehlerPh @CornelyOliver @martinhoenigl
& others
journalofinfection.com/artic…
Honored, grateful and humbled - I have been ID’ed as a Fellow of @IDSAInfo. Thanks to all colleagues, collaborators and mentors, especially @CornelyOliver and to the ID Team @UKKoeln @UniCologne #WeAreID #ThinkFungus
Philipp Koehler retweeted
Invasive Fungal Diseases in Adult Patients in Intensive Care Unit (FUNDICU): 2024 consensus definitions from ESGCIP, EFISG, ESICM, ECMM, MSGERC, ISAC, and ISHAM.
This is a great achievement which confirms many years of hard work.
Many thanks to all the contributors.
@yourICM
link.springer.com/article/10…
Philipp Koehler retweeted
FUNDICU invasive fungal diseases in adults in #ICU consensus definitions by ESGCIP @efisg_escmid @ESICM @eurconfmedmycol @MSG_ERC ISAC
@ISHAM_Mycology for
🍄invasive candidiasis
🍄invasive aspergillosis
in non-neutropenic pts w/o classical host factors
🖇️ bit.ly/3PAqqrJ
Philipp Koehler retweeted
🔥🔥 Public consultation #Global #Candida #Guideline NOW ➡️clinicalsurveys.net/uc/GL_Ca… 🙏🙏🙏@eurconfmedmycol @ISHAM_Mycology @neil_gow @martinhoenigl @ProfMBassetti @OKurzai @DrLuisO @RosanneSprute @SalmantonGarcia @BirgitWillinger Please RT📢need your input📢
Philipp Koehler retweeted
💊 Phase 1b safety and pharmacokinetics of intravenous and oral #formanogepix in patients with acute myeloid leukaemia and neutropenia
@CornelyOliver @KoehlerPh
academic.oup.com/jac/advance…
Philipp Koehler retweeted
🆕️⚡️🔥 #JAC 🌟s @JannikStemler @CornelyOliver @RosanneSprute @MellinghoffSC @KoehlerPh @martinhoenigl
Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies
2022 update German Society for Haematology&Medical Oncology academic.oup.com/jac/article…
Philipp Koehler retweeted
📢finally out in @OUPAcademic JAC🥳
Antifungal prophylaxis guideline by ID Working Group @dgho_eV
tinyurl.com/mr3948zf
✅evidence-based
✅overview tables
✅study summaries in suppl
Great team effort! @CornelyOliver @RosanneSprute @MellinghoffSC @KoehlerPh @martinhoenigl
Philipp Koehler retweeted
#Pre_print 📢3rd doses of #Pfizer or #Moderna #COVID19 increase ↗️antibodies 14 days post-#vaccination in #elderly
Full details of this @vaccelerate_eu #RCT👇👇
papers.ssrn.com/sol3/Deliver…
@JannikStemler @KoehlerPh @CornelyOliver @UKKoeln @EU_HaDEA @CECAD_ @DZIF_ @DZIFBonnKoeln
🔥Which 🍄 trial do we need? Combination treatment - TMP-SMX plus an echinocandin for Pneumocystis jirovecii pneumonia in non-HIV infected patients - find our thoughts and ideas @CMIJournal 👉authors.elsevier.com/a/1hAxN… by @jprattes, @CornelyOliver & colleagues from @UKKoeln, @CECAD_
Philipp Koehler retweeted
📢 Call for RCT investigating trimetoprim-sulfamethoxazole + echinocandin for #Pneumocystis pneumonia in non-HIV patients
@CornelyOliver @jprattes @KoehlerPh
sciencedirect.com/science/ar…
Philipp Koehler retweeted
57. Wissenschaftliche Jahrestagung 27. bis 29. September 2023
in Frankfurt/Main
REMINDER: Call for Abstracts –
New Deadline 26. Mai 2023 –
online unter dmykg-kongress.de
Philipp Koehler retweeted
This may be the 1st #comparison between #paxlovid and #molnupiravir - Let Jon and authors know what you think about it!
#Molnupiravir & #Nirmatrelvir have same target: mild #COVID19, both are #oral & prevent #progression BUT #Molnupiravir is NOT licensed in 🇪🇺
In #EPICOVIDEHA we've compared both drugs in #hem_onc &... Mortality is NOT significantly different!
🔗Preprint: papers.ssrn.com/sol3/papers.…
Philipp Koehler retweeted
Klimawandel: Pilzinfektionen nehmen weltweit zu - ZDFheute zdf.de/nachrichten/panorama/…
Philipp Koehler retweeted
New in @TheLancetInfDis>
Guideline adherence and survival of patients with #candidaemia in Europe: results from the ECMM #Candida III multinational European observational cohort study
thelancet.com/journals/lanin…